Management of osteoporosis
暂无分享,去创建一个
[1] Jung-Tung Liu,et al. Balloon kyphoplasty versus vertebroplasty for treatment of osteoporotic vertebral compression fracture: a prospective, comparative, and randomized clinical study , 2010, Osteoporosis International.
[2] J. Eisman,et al. Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] David J. Wilson,et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. , 2009, The New England journal of medicine.
[4] R. Buchbinder,et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. , 2009, The New England journal of medicine.
[5] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[6] B. Steele,et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study , 2009, Osteoporosis International.
[7] S. Boonen,et al. Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] S. Khosla,et al. New selective estrogen and androgen receptor modulators , 2009, Current opinion in rheumatology.
[9] J. Ringe,et al. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis , 2009, Rheumatology International.
[10] H. Taylor. Designing the ideal selective estrogen receptor modulator-an achievable goal? , 2009, Menopause.
[11] L. Assael,et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[12] S. Silverman. Selecting Patients for Osteoporosis Therapy , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] D. Kiel,et al. Dietary Calcium and Serum 25‐Hydroxyvitamin D Status in Relation to BMD Among U.S. Adults , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] Kim Brixen,et al. Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS) , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] S. Judd,et al. Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[16] E John Orav,et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. , 2009, Archives of internal medicine.
[17] H. Genant,et al. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment , 2009, Current medical research and opinion.
[18] R. Recker,et al. Safety of bisphosphonates in the treatment of osteoporosis. , 2009, The American journal of medicine.
[19] S. Silverman,et al. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. , 2009, The American journal of medicine.
[20] I. Reid,et al. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. , 2009, The Journal of clinical endocrinology and metabolism.
[21] V. Vogel. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial , 2009, Expert review of anticancer therapy.
[22] R. O’Keefe,et al. Activation of β‐Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis‐Like Phenotype in Adult β‐Catenin Conditional Activation Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] Claus Christiansen,et al. Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] A. Bergland,et al. Risk of hip fractures in soft protected, hard protected, and unprotected falls , 2008, Injury Prevention.
[25] S. Boonen,et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. , 2008, The Journal of clinical endocrinology and metabolism.
[26] S. Boonen,et al. Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] M. Tinetti. Multifactorial Fall‐Prevention Strategies: Time to Retreat or Advance , 2008, Journal of the American Geriatrics Society.
[28] A. Campbell,et al. Effectiveness of a Falls‐and‐Fracture Nurse Coordinator to Reduce Falls: A Randomized, Controlled Trial of At‐Risk Older Adults , 2008, Journal of the American Geriatrics Society.
[29] W. J. Mulder,et al. Lack of Effectiveness of a Multidisciplinary Fall‐Prevention Program in Elderly People at Risk: A Randomized, Controlled Trial , 2008, Journal of the American Geriatrics Society.
[30] B. Carlin,et al. Effect of dissemination of evidence in reducing injuries from falls. , 2008, The New England journal of medicine.
[31] Jacques P. Brown,et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. , 2008, The Journal of rheumatology.
[32] T. Spector,et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. , 2008, Arthritis and rheumatism.
[33] D. Lorich,et al. Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.
[34] Kenneth A. Harris,et al. Association between alcohol consumption and both osteoporotic fracture and bone density. , 2008, The American journal of medicine.
[35] R. Lindsay,et al. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy , 2008, Osteoporosis International.
[36] F. McAlister,et al. Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial , 2008, Canadian Medical Association Journal.
[37] L. Melton,et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA , 2008, Osteoporosis International.
[38] C. Christiansen,et al. Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2‐Yr Results of a Randomized, Double‐Blind, Placebo‐, and Active‐Controlled Study , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] P. Miller,et al. Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[40] S. Boonen,et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2007, The New England journal of medicine.
[41] M Alan Brookhart,et al. Osteoporosis Improvement: A Large‐Scale Randomized Controlled Trial of Patient and Primary Care Physician Education , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[42] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[43] K. Kavanagh,et al. Bisphosphonates , 2007, Annals of the New York Academy of Sciences.
[44] J. Wark,et al. The effects of smoking on bone health. , 2007, Clinical science.
[45] J. Bilezikian,et al. Bone turnover 18 months after a single intravenous dose of zoledronic acid , 2007, International journal of clinical practice.
[46] R. Baron,et al. Wnt signaling and the regulation of bone mass , 2007, Current osteoporosis reports.
[47] G. Karsenty,et al. In vivo analysis of Wnt signaling in bone. , 2007, Endocrinology.
[48] S. Cummings,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[49] E. Lewiecki,et al. A review of strontium ranelate and its effect on DXA scans. , 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[50] J. Eisman,et al. Risk factors for fracture in nonosteoporotic men and women. , 2007, The Journal of clinical endocrinology and metabolism.
[51] E. Briganti,et al. Exercise and Calcium Combined Results in a Greater Osteogenic Effect Than Either Factor Alone: A Blinded Randomized Placebo‐Controlled Trial in Boys , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[52] O. Vasiljeva,et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. , 2007, Current pharmaceutical design.
[53] S. Cummings,et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.
[54] M. Tinetti,et al. Fall-risk evaluation and management: challenges in adopting geriatric care practices. , 2006, The Gerontologist.
[55] R. Marcus,et al. Osteosarcoma and Teriparatide? , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[56] T. Keaveny,et al. Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[57] M. Drezner,et al. Osteonecrosis of the Jaw: More Research Needed , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[58] E. Barrett-Connor,et al. Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.
[59] S. Boonen,et al. Strontium Ranelate Reduces the Risk of Vertebral and Nonvertebral Fractures in Women Eighty Years of Age and Older , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[60] C. Christiansen,et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. , 2006, Arthritis and rheumatism.
[61] Y. Yazici,et al. Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.
[62] J. Kalmar,et al. Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws , 2006, Annals of Internal Medicine.
[63] O. MacDougald,et al. Regulation of bone mass by Wnt signaling. , 2006, The Journal of clinical investigation.
[64] C. Turner,et al. Bone Strength: Current Concepts , 2006, Annals of the New York Academy of Sciences.
[65] T. Spector,et al. Strontium Ranelate Reduces the Risk of Vertebral Fractures in Patients With Osteopenia , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[66] K. Ishikawa-Takata,et al. The effects of Tai Chi Chuan on physiological function and fear of falling in the less robust elderly: an intervention study for preventing falls. , 2006, Archives of gerontology and geriatrics.
[67] P. Farahmand,et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study , 2006, Rheumatology International.
[68] C. Deal,et al. Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis – a Clinical Update on Efficacy and Safety , 2006, Women's health.
[69] M. Drezner,et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study , 2005, Annals of the rheumatic diseases.
[70] S. Boonen,et al. Safety and Efficacy of Risedronate in Patients With Age‐Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[71] A. Tashjian,et al. Teriparatide [Human PTH(1‐34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[72] E. Schwartz,et al. Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[73] S. Cummings,et al. Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[74] D. Newitt,et al. Effects of Salmon Calcitonin on Trabecular Microarchitecture as Determined by Magnetic Resonance Imaging: Results From the QUEST Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[75] D. Black,et al. Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.
[76] R. Lindsay,et al. Daily and cyclic parathyroid hormone in women receiving alendronate. , 2005, The New England journal of medicine.
[77] G. Dalsky,et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. , 2005, Archives of internal medicine.
[78] G. Chatellier,et al. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism , 2005, BMJ : British Medical Journal.
[79] Kenton R Kaufman,et al. Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program. , 2005, Mayo Clinic proceedings.
[80] Steven L Wolf,et al. Reduction in Fear of Falling Through Intense Tai Chi Exercise Training in Older, Transitionally Frail Adults , 2005, Journal of the American Geriatrics Society.
[81] G. Dalsky,et al. Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[82] Anna Nordström,et al. Bone gained from physical activity and lost through detraining: a longitudinal study in young males , 2005, Osteoporosis International.
[83] W. Grant,et al. Benefits and requirements of vitamin D for optimal health: a review. , 2005, Alternative medicine review : a journal of clinical therapeutic.
[84] C. Cooper,et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial , 2005, The Lancet.
[85] J. Reginster,et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.
[86] J. Kaufman,et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy , 2005, Osteoporosis International.
[87] H. Genant,et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. , 2005, The Journal of clinical endocrinology and metabolism.
[88] J. Zerwekh,et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.
[89] M. D. de Broe,et al. Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats. , 2005, Kidney international.
[90] A. LaCroix,et al. Risk Factors Associated with Acute Pyelonephritis in Healthy Women , 2005, Annals of Internal Medicine.
[91] H. Meinzer,et al. Treatment of Painful Vertebral Fractures by Kyphoplasty in Patients With Primary Osteoporosis: A Prospective Nonrandomized Controlled Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[92] K. Prestwood,et al. Bone health and aging: implications for menopause. , 2004, Endocrinology and metabolism clinics of North America.
[93] S. Cummings,et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.
[94] Hiroshi Ohshima,et al. Intravenous Pamidronate Prevents Femoral Bone Loss and Renal Stone Formation During 90‐Day Bed Rest , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[95] C. Christiansen,et al. Changes in bone density and turnover after alendronate or estrogen withdrawal , 2004, Menopause.
[96] D. Mellström,et al. Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.
[97] S. Dhaliwal,et al. Physical Activity and Calcium Consumption Are Important Determinants of Lower Limb Bone Mass in Older Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[98] I. Lieberman,et al. Primary and Secondary Osteoporosis' Incidence of Subsequent Vertebral Compression Fractures After Kyphoplasty , 2004, Spine.
[99] S. Cummings,et al. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial , 2004, Obstetrics and gynecology.
[100] Richard Eastell,et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. , 2004, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[101] C. Christiansen,et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[102] E. Barrett-Connor,et al. Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[103] W. Flanders,et al. The association between physical activity and forearm bone mineral density in healthy premenopausal women. , 2004, Journal of women's health.
[104] B. Ettinger,et al. Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[105] J. Manson,et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial , 2004 .
[106] John Robbins,et al. National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.
[107] R. Chlebowski,et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. , 2004, The New England journal of medicine.
[108] H. Minne,et al. Effects of a New Spinal Orthosis on Posture, Trunk Strength, and Quality of Life in Women with Postmenopausal Osteoporosis: A Randomized Trial , 2004, American journal of physical medicine & rehabilitation.
[109] R. Eastell,et al. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.
[110] Johanna W Lampe,et al. Antibiotic use in relation to the risk of breast cancer , 2004, JAMA.
[111] C. Rubin,et al. Prevention of Postmenopausal Bone Loss by a Low‐Magnitude, High‐Frequency Mechanical Stimuli: A Clinical Trial Assessing Compliance, Efficacy, and Safety , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[112] L. Hofbauer,et al. Novel Aspects on RANK Ligand and Osteoprotegerin in Osteoporosis and Vascular Disease , 2003, Calcified Tissue International.
[113] A. LaCroix,et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.
[114] J. Finkelstein,et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.
[115] Mary L Bouxsein,et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.
[116] R. Marx. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[117] E. Barrett-Connor,et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study , 2003, Menopause.
[118] O. Johnell,et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. , 2003, Bone.
[119] M. Kulldorff,et al. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. , 2003, JAMA.
[120] Mary Cushman,et al. Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.
[121] R. Eastell,et al. Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[122] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[123] M. Grabois,et al. Health Professional's Guide to Rehabilitation of the Patient with Osteoporosis , 2003, Osteoporosis International.
[124] Lex M Bouter,et al. Prevention of hip fractures by external hip protectors: a randomized controlled trial. , 2003, JAMA.
[125] Cecilia A. Hale,et al. Calcium Absorption Varies within the Reference Range for Serum 25-Hydroxyvitamin D , 2003, Journal of the American College of Nutrition.
[126] A. Licata. Osteoporosis in men: suspect secondary disease first. , 2003, Cleveland Clinic journal of medicine.
[127] U. Barzel. Recommended testing in patients with low bone density. , 2003, The Journal of clinical endocrinology and metabolism.
[128] R. Doll,et al. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.
[129] L. Hartmann,et al. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.
[130] M. Holick,et al. Vitamin D and bone health in postmenopausal women. , 2003, Journal of women's health.
[131] R. Lew,et al. Effects of Vitamin D and Calcium Supplementation on Falls: A Randomized Controlled Trial , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[132] C. Cooper,et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. , 2003, Bone.
[133] P. Gerdhem,et al. Effects of Cigarette-Smoking on Bone Mass as Assessed by Dual-Energy X-ray Absorptiometry and Ultrasound , 2002, Osteoporosis International.
[134] H. Deutschmann,et al. Search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density , 2002, Journal of internal medicine.
[135] M. Kulldorff,et al. Effects of smoking cessation or reduction on hormone profiles and bone turnover in postmenopausal women. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[136] J. Gallagher,et al. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. , 2002, The Journal of clinical endocrinology and metabolism.
[137] Gynecologists. ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002. , 2002, Obstetrics and gynecology.
[138] D. Bauer,et al. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? , 2002, Mayo Clinic proceedings.
[139] D. Meier,et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. , 2002, The Journal of clinical endocrinology and metabolism.
[140] R. Heaney. Effects of caffeine on bone and the calcium economy. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[141] S. Cummings,et al. Does Follow-up of Osteoporotic Women Treated with Antiresorptive Therapies Improve Effectiveness? , 2002, Osteoporosis International.
[142] Jacques P. Brown,et al. The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis , 2002, Calcified Tissue International.
[143] G. Guyatt,et al. V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women , 2002 .
[144] C. Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[145] M. Schlichting,et al. Combined Calcium and Vitamin D3 Supplementation in Elderly Women: Confirmation of Reversal of Secondary Hyperparathyroidism and Hip Fracture Risk: The Decalyos II Study , 2002, Osteoporosis International.
[146] B. Chabner,et al. Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1‐34 in the Treatment of Osteoporosis in Men and Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[147] W. O'Fallon,et al. Secondary osteoporosis and the risk of distal forearm fractures in men and women. , 2002, Bone.
[148] P. Delmas,et al. Treatment of postmenopausal osteoporosis , 2002, The Lancet.
[149] Hashem Younes,et al. Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. , 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[150] J. Adachi,et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. , 2002, Archives of internal medicine.
[151] S. Cummings,et al. Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.
[152] E. Barrett-Connor,et al. Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial , 2002 .
[153] G. Mundy. Osteoporosis: pathophysiology and non-pharmacological management. , 2001, Best practice & research. Clinical rheumatology.
[154] R Mendelsohn,et al. Spectroscopic Characterization of Collagen Cross‐Links in Bone , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[155] P. Kostenuik,et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. , 2001, Endocrinology.
[156] S. Adami,et al. Alendronate for the Treatment of Osteoporosis in Men , 2001, Calcified Tissue International.
[157] C. Rey,et al. Mechanisms of Action and Therapeutic Potential of Strontium in Bone , 2001, Calcified Tissue International.
[158] P. Fratzl,et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. , 2001, Bone.
[159] Mark A. Reiley,et al. New Technologies in Spine: Kyphoplasty and Vertebroplasty for the Treatment of Painful Osteoporotic Compression Fractures , 2001, Spine.
[160] J. Manson,et al. Clinical practice. Postmenopausal hormone-replacement therapy. , 2001, The New England journal of medicine.
[161] D. Torgerson,et al. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. , 2001, JAMA.
[162] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[163] P Geusens,et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.
[164] J. Gallagher,et al. Role of estrogens in the management of postmenopausal bone loss. , 2001, Rheumatic diseases clinics of North America.
[165] C. Christiansen,et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. , 2000, Archives of internal medicine.
[166] P Kannus,et al. Prevention of hip fracture in elderly people with use of a hip protector. , 2000, The New England journal of medicine.
[167] S. Cummings,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.
[168] J. Rodriguez-Portales,et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. , 2000, The Journal of clinical endocrinology and metabolism.
[169] D. Kiel,et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.
[170] P. Kostenuik,et al. Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis , 2000, The Journal of experimental medicine.
[171] C. Rosen,et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. , 2000, The Journal of clinical endocrinology and metabolism.
[172] E. Vittinghoff,et al. Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.
[173] J. Reginster,et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. , 2000, The Journal of clinical endocrinology and metabolism.
[174] M. Davie,et al. Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men , 2000, Annals of the rheumatic diseases.
[175] J A Stevens,et al. Reducing falls and resulting hip fractures among older women. , 2000, Home care provider.
[176] D. Kiel,et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. , 2000 .
[177] R. Hoover,et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.
[178] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[179] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[180] V. Beral,et al. Hormone Replacement Therapy: Patient Education Crucial , 1999, The Lancet.
[181] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[182] D. Felsenberg,et al. Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.
[183] F. Grodstein,et al. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.
[184] M. D. de Broe,et al. Strontium and Bone , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[185] J. Glowacki,et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. , 1999, JAMA.
[186] G. Colditz,et al. Smoking, smoking cessation, and risk of hip fracture in women. , 1999, The American journal of medicine.
[187] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[188] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[189] B. Riggs,et al. Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[190] E. Barrett-Connor. Fortnightly review: Hormone replacement therapy , 1998 .
[191] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[192] M. Holick,et al. Redefining vitamin D insufficiency , 1998, The Lancet.
[193] J. Eisman,et al. Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial , 1998, Annals of Internal Medicine.
[194] J. Digennaro,et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. , 1998, The Journal of clinical endocrinology and metabolism.
[195] C. Christiansen,et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.
[196] G. Lyritis,et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. , 1997, Acta orthopaedica Scandinavica. Supplementum.
[197] G E Dallal,et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.
[198] Jacques P. Brown,et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.
[199] R. Balena,et al. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. , 1997, The American journal of medicine.
[200] J. Levine,et al. Esophageal stricture associated with alendronate therapy. , 1997, The American journal of medicine.
[201] Ego Seeman,et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.
[202] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[203] Kenneth K Wang,et al. Esophagitis associated with the use of alendronate. , 1996, The New England journal of medicine.
[204] I. Reid,et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.
[205] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[206] S. Cummings,et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.
[207] M. Tinetti,et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. , 1994, The New England journal of medicine.
[208] L. Rubenstein,et al. Falls in the Nursing Home , 1994, Annals of Internal Medicine.
[209] K. Overgaard. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study , 1994, Calcified Tissue International.
[210] I. Reid,et al. Effect of calcium supplementation on bone loss in postmenopausal women. , 1993, The New England journal of medicine.
[211] F Duboeuf,et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.
[212] C. Slemenda,et al. Calcium supplementation and increases in bone mineral density in children. , 1992, The New England journal of medicine.
[213] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[214] R. Prince,et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. , 1991, The New England journal of medicine.
[215] B. Dawson-Hughes,et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. , 1990 .
[216] W. Mysiw,et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[217] H. Genant,et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[218] M. Tinetti,et al. Prevention of falls among the elderly. , 1989, The New England journal of medicine.
[219] Chang Lw,et al. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. , 1989 .
[220] C. Christiansen,et al. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. , 1987, The New England journal of medicine.
[221] H. DeLuca,et al. Strontium Induced Rickets: Metabolic Basis , 1971, Science.
[222] G. Keating,et al. Raloxifene , 2012, Drugs.
[223] P. Sambrook. Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw , 2009, Nature Clinical Practice Rheumatology.
[224] E. Seeman. Loading and bone fragility , 2009, Journal of Bone and Mineral Metabolism.
[225] P. Kostenuik,et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. , 2008, Endocrine reviews.
[226] N. Hamdy. Denosumab: RANKL inhibition in the management of bone loss. , 2008, Drugs of today.
[227] G. Dalsky,et al. Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results , 2008 .
[228] E. Brown,et al. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. , 2007, Sub-cellular biochemistry.
[229] M. Passeri,et al. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study , 2007, Calcified Tissue International.
[230] David J Torgerson,et al. Primary care Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D 3 ) for prevention of fractures in primary care , 2005 .
[231] E. Barrett-Connor,et al. The rise and fall of menopausal hormone therapy. , 2005, Annual review of public health.
[232] H. Rodbard,et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[233] W. Nagler,et al. Current medical, rehabilitation, and surgical management of vertebral compression fractures. , 2003, Journal of women's health.
[234] O. Johnell,et al. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. , 2002, Bone.
[235] Kay Dickersin,et al. Osteoporosis prevention, diagnosis, and therapy. , 2000, NIH consensus statement.
[236] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[237] S. Epstein,et al. Drug-Induced Bone Loss , 2000, Osteoporosis International.
[238] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[239] P. Beighton,et al. 0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(12):6392–6395 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2005-1235 Bone Mineral Density in Sclerosteosis; Affected Individuals and Gene Carriers , 2022 .